|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Chemocentryx, Inc. (CCXI) |
|
|
$51.99 0.00 (0.00%) as of 4:30 Wed 10/19
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
69,210,000 |
| Market
Cap: |
3.60(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$51.99 - $51.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ChemoCentryx is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. Co. targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the U.S., Co. markets TAVNEOS® (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis, and microscopic polyangiitis. Co. is also developing TAVNEOS for the treatment of severe Hidradenitis Suppurativa.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
217,623 |
| Total Sell Value |
$0 |
$0 |
$0 |
$10,849,434 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
6 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jain Rita |
EVP, Chief Medical Officer |
• • – |
2022-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,726 |
35,863 |
|
- |
|
| Parker Geoffrey M. |
Director |
– • – |
2022-05-20 |
4 |
OE |
$0.00 |
$0 |
I/I |
7,726 |
21,076 |
|
- |
|
| Parker Geoffrey M. |
Director |
– • – |
2022-05-02 |
4 |
OE |
$14.42 |
$180,250 |
D/D |
12,500 |
124,413 |
|
- |
|
| Jain Rita |
EVP, Chief Medical Officer |
• • – |
2022-03-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,251 |
28,137 |
|
- |
|
| Feczko Joseph M |
Director |
– • – |
2022-01-21 |
4 |
OE |
$14.42 |
$577,750 |
D/D |
37,500 |
148,127 |
|
- |
|
| Kanaya Susan M |
EVP, CFO and Sec. |
• • – |
2022-01-01 |
4 |
D |
$36.41 |
$613,399 |
I/I |
(16,847) |
132,717 |
|
- |
|
| Kanaya Susan M |
EVP, CFO and Sec. |
• • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
I/I |
30,799 |
149,564 |
|
- |
|
| Schall Thomas J. |
President and CEO |
• • – |
2022-01-01 |
4 |
D |
$36.41 |
$1,663,864 |
D/D |
(45,698) |
2,393,352 |
|
- |
|
| Schall Thomas J. |
President and CEO |
• • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
84,234 |
2,439,050 |
|
- |
|
| Cappel Markus J. |
Chief Bus. Officer & Treasurer |
• – – |
2022-01-01 |
4 |
D |
$36.41 |
$420,099 |
D/D |
(11,538) |
95,222 |
|
- |
|
| Cappel Markus J. |
Chief Bus. Officer & Treasurer |
• – – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,934 |
106,760 |
|
- |
|
| Tyree James L |
Director |
– • – |
2021-12-17 |
4 |
AS |
$33.52 |
$1,313,165 |
D/D |
(37,500) |
15,275 |
|
-46% |
|
| Tyree James L |
Director |
– • – |
2021-12-17 |
4 |
OE |
$12.62 |
$495,750 |
D/D |
37,500 |
52,775 |
|
- |
|
| Schall Thomas J. |
President and CEO |
• • – |
2021-12-01 |
4 |
OE |
$10.27 |
$499,994 |
D/D |
45,936 |
2,354,816 |
|
- |
|
| Vifor Fresenius Medical Care Renal Pharma Ltd. |
10% Owner |
– – • |
2021-10-12 |
4 |
S |
$39.43 |
$157,720,000 |
I/I |
(4,000,000) |
5,194,085 |
|
20% |
|
| Tyree James L |
Director |
– • – |
2021-05-21 |
4 |
AS |
$9.76 |
$23,956 |
D/D |
(2,454) |
15,275 |
|
78% |
|
| Tyree James L |
Director |
– • – |
2021-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,660 |
17,729 |
|
- |
|
| Parker Geoffrey M. |
Director |
– • – |
2021-05-21 |
4 |
OE |
$0.00 |
$0 |
I/I |
4,660 |
13,350 |
|
- |
|
| Jain Rita |
Director |
– • – |
2021-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,660 |
22,886 |
|
- |
|
| Edwards Thomas A. |
Director |
– • – |
2021-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
7,726 |
127,583 |
|
- |
|
| Feczko Joseph M |
Director |
– • – |
2021-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
7,726 |
110,627 |
|
- |
|
| Butt Tausif |
EVP, Chief Operating Officer |
• – – |
2021-05-07 |
4 |
B |
$11.06 |
$120,241 |
D/D |
10,870 |
10,870 |
2.74 |
53% |
|
| Jain Rita |
Director |
– • – |
2021-03-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,251 |
18,226 |
|
- |
|
| Parker Geoffrey M. |
Director |
– • – |
2021-03-10 |
4 |
GD |
$0.00 |
$0 |
I/I |
4,000 |
8,690 |
|
- |
|
| Parker Geoffrey M. |
Director |
– • – |
2021-03-05 |
4 |
S |
$55.89 |
$1,691,468 |
I/I |
(30,000) |
12,690 |
|
73% |
|
472 Records found
|
|
Page 2 of 19 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
